By contrast, genetic variation in the targets of insulin and its analogues, and of sulfonylurea, were not associated with RA risk (OR [95%CI]: 0.83 [0.44–1.55] and 1.25 [0.78-2.00], respectively). Here, INS is linked to rheumatoid arthritis.